Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2025-12-24 @ 2:59 PM
NCT ID:
NCT06286059
Eligibility Criteria:
Inclusion Criteria:
* Patients admitted to CCU with CAD.
* Patients underwent successful complex PCI defined as multivessel disease, more than two lesions, high coronary lesion complexity, chronic total occlusion, lesion length \>30 mm, or bifurcation.
* Patients at high or very high risk for CA-AKI based on Mehran-2 CA-AKI Risk Score (Model 2).
Exclusion Criteria:
* Patients with end stage renal disease on regular dialysis.
* Patients with failed PCI revascularization.
* Patients presented with STEMI and underwent primary PCI.
* Patients presented with high risk NSTEMI defined as elevated cardiac enzymes with chest pain refractory to medications and/or dynamic ST changes.
* Patients presented with cardiogenic shock.
* Patients presented with any degree of heart block.
* Patients with of history of asthma or hypersensitive for phentolamine.
* Patients on α-blockers, barbiturates or antipsychotic treatment.
* Patients intolerant to phentolamin with significant hemodynamic changes defined as \>20% drop of systolic blood pressure (SBP) or \>20% increase of heart rate (HR) after loading dose of phentolamine.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06286059
Study Brief:
Protocol Section:
NCT06286059